<SEC-DOCUMENT>0000078003-18-000101.txt : 20181219
<SEC-HEADER>0000078003-18-000101.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219085919
ACCESSION NUMBER:		0000078003-18-000101
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181219
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		181242295

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pfe_8kx12192018.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCBECD66B3664BD1180BBC616AEEE2388"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:center;-sec-extract:summary;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES </font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of report (Date of earliest event reported): December 19, 2018</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">PFIZER INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter) </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.42300194931774%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1-3619</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13-5315170</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Commission</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">235 East 42nd Street</font></div><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New York, New York</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (212) 733-2323 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Former Name or Former Address, if changed since last report) </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company  </font><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:144%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On December 19, 2018, Pfizer Inc. (&#8220;Pfizer&#8221;) issued a press release announcing that Pfizer, GlaxoSmithKline plc (&#8220;GSK&#8221;) and GlaxoSmithKline Consumer Healthcare Holdings Limited, a wholly owned subsidiary of GSK, entered into an agreement pursuant to which, on the terms and subject to the conditions contained therein, Pfizer and GSK agreed to combine their respective consumer healthcare businesses to form a new consumer healthcare joint venture.  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The press release announcing the proposed transaction is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item&#160;7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;Exhibits</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexh.htm"><font style="font-family:inherit;font-size:12pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexh.htm"><font style="font-family:inherit;font-size:12pt;">Press Release of Pfizer Inc., dated December 19, 2018.</font></a></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT INDEX</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexh.htm"><font style="font-family:inherit;font-size:12pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexh.htm"><font style="font-family:inherit;font-size:12pt;">Press Release of Pfizer Inc., dated December 19, 2018</font></a><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SIGNATURE</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.68615984405457%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:23%;"></td><td style="width:8%;"></td><td style="width:7%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PFIZER INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Margaret M. Madden</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Margaret M. Madden</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Senior Vice President and Corporate Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chief Governance Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">December 19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseexh.htm
<DESCRIPTION>EXHIBIT 99.1 PFIZER INC. PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s52F2554A7842371C64ADC62CF3890E24"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit 99.1 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;"><img src="pressreleaseexhimage1.jpg" alt="pressreleaseexhimage1.jpg" style="height:62px;width:106px;"></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:559px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:178px;"></td><td style="width:48px;"></td><td style="width:68px;"></td><td style="width:264px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For immediate release:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pfizer U.S. Media contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">December 19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Joan Campion</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">212-733-2798</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Joan.Campion@pfizer.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pfizer Europe Media Contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andrew Widger</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;+44-1737-330909</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andrew.Widger@pfizer.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Investor Contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Charles Triano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">212-733-3901</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Charles.E.Triano@pfizer.com</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PFIZER AND GLAXOSMITHKLINE ANNOUNCE JOINT VENTURE TO CREATE A PREMIER GLOBAL CONSUMER HEALTHCARE COMPANY</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">- - - </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Establishes a new focused global consumer healthcare business with the independence and sustainability to deliver significant value</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">- - - </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Equity split of 32% Pfizer and 68% GlaxoSmithKline</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NEW YORK, NY, December 19 - Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.  The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline&#8217;s existing consumer healthcare business.  The 2017 global sales for the combined business were approximately $12.7 billion.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;We are pleased to announce this new joint venture for Pfizer Consumer Healthcare, delivering on our commitment to complete the strategic review for this business in 2018,&#8221; stated Ian Read, chairman and current chief executive officer, Pfizer.  &#8220;Pfizer and GSK have an excellent track record of creating successful collaborations, and we look forward to working together again to unlock the potential of our combined consumer healthcare businesses.&#8221; </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Under the terms of the transaction, Pfizer will receive a 32% equity stake in the joint venture, entitling Pfizer to its pro rata share of the joint venture&#8217;s earnings and dividends, which will be paid on a quarterly basis.  Pfizer will have the right to appoint three out of the nine members of the joint venture&#8217;s board.  The transaction is expected to deliver $650 million in peak cost synergies and to be slightly accretive for Pfizer in each of the first three years after the close of the transaction, which is anticipated during the second half of 2019, subject to receipt of GSK shareholder approval and regulatory approvals, and satisfaction of other customary closing conditions.  </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As Pfizer will own less than 50% of the joint venture, Pfizer anticipates deconsolidating Pfizer Consumer Healthcare from its financial statements following the closing of the transaction.  In the near- to medium-term, this deconsolidation is not expected to have a material impact on Pfizer&#8217;s top-line growth.  In addition, given the Consumer Healthcare business records lower margins than Pfizer&#8217;s other businesses, the deconsolidation is expected to have a slight positive impact on Pfizer&#8217;s operating margins over the next several years.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Following the integration of the combined business, GSK intends to separate the joint venture as an independent company via a demerger of its equity interest to its shareholders and a listing of the Consumer Healthcare business on the UK equity market.  GSK will have the sole right to decide whether and when to initiate a separation and listing for a period of five years from closing of the proposed transaction.  GSK may also sell all or part of its stake in the joint venture in a contemporaneous IPO.  </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Should a separation and listing occur during the first five years after closing, Pfizer has the option to participate through the distribution of its equity interest in the joint venture to its shareholders or the sale of its equity interest in a contemporaneous IPO.  After the fifth anniversary of the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">closing of the proposed transaction, both GSK and Pfizer will have the right to decide whether and when to initiate a separation and public listing of the joint venture.  </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The combination of these leading businesses with distinct regional and category strengths will be more sustainable and broader in scope than either company individually,&#8221; said Albert Bourla, chief operating officer and incoming chief executive officer, Pfizer.  &#8220;We believe that this joint venture is a great opportunity to ensure the future success of Pfizer Consumer Healthcare while unlocking meaningful after-tax value for Pfizer shareholders.&#8221; </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The joint venture will be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health and will be the largest global consumer healthcare business.  In addition, the joint venture is expected to be the first or second largest consumer healthcare player in key geographies, including the United States, Europe, China, India and Australasia.  The joint venture will operate globally under the GSK Consumer Healthcare name.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The transaction is a testament to the success of our Consumer Healthcare business, including its excellent reputation, talented colleagues, high-quality products and market reach,&#8221; said Chris Slager, president, Pfizer Consumer Healthcare.  &#8220;The dedication and hard work of the Pfizer Consumer Healthcare team is impressive and inspiring.&#160; I am proud of our colleagues around the world who are passionate about&#160;the success of this business and the important role it plays in empowering consumers to take health and wellness into their own hands.&#8221;</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emma Walmsley, GSK CEO, will be Chair of the new joint venture. Brian McNamara, currently CEO GSK Consumer Healthcare, will be CEO of the new joint venture and Tobias Hestler, currently CFO GSK Consumer Healthcare, will be CFO.  </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Until separation, the joint venture will be consolidated in GSK&#8217;s financial statements.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the year ended December 31, 2017, the Pfizer Consumer Healthcare business recorded revenues of approximately $3.5 billion and the GSK Consumer Healthcare business recorded revenues of approximately $9.2 billion. </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">GSK has agreed to pay a break fee of $900 million if (i) the GSK Board of Directors changes, withdraws or qualifies its recommendation of the transaction to its shareholders for approval; (ii) GSK&#8217;s shareholders vote on the proposed transaction and do not approve it; or (iii) GSK&#8217;s shareholders do not approve the proposed transaction by September 30, 2019 (subject to extension in certain circumstances).</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Centerview Partners LLC, Guggenheim Securities, LLC and Morgan Stanley &amp; Co. LLC served as Pfizer&#8217;s financial advisors, Wachtell, Lipton, Rosen &amp; Katz, and Clifford Chance LLP served as its legal advisors, and Skadden, Arps, Slate, Meagher &amp; Flom LLP served as its tax advisor.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#fefefe;font-style:italic;">DISCLOSURE NOTICE</font><font style="font-family:inherit;font-size:11pt;background-color:#fefefe;">:&#160;</font><font style="font-family:inherit;font-size:11pt;background-color:#fefefe;font-style:italic;">The information contained in this release is as of December 19, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#fefefe;font-style:italic;">This release contains forward-looking information related to Pfizer, Pfizer&#8217;s and GSK&#8217;s consumer healthcare businesses and an agreement to create a joint venture to combine Pfizer&#8217;s and GSK&#8217;s consumer healthcare businesses that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed joint venture and transaction, anticipated accretion and cost savings, the companies&#8217; plans, objectives, expectations and intentions, the financial condition, results of operations and business of the proposed joint venture, the proposed joint venture&#8217;s products and potential, the anticipated impact of the deconsolidation of the Pfizer Consumer Healthcare business from Pfizer&#8217;s financial statements, GSK&#8217;s future plans to separate the joint venture as an independent company, and the anticipated timing of closing of the transaction. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the transaction (including the failure to obtain necessary regulatory and GSK shareholder approvals) in the anticipated timeframe or at all and the possibility that the transaction does not close; risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits and cost savings from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; the possibility that a future separation of the joint venture may not occur; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the proposed transaction on the market price of Pfizer&#8217;s common stock and on Pfizer&#8217;s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed transaction; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; and competitive developments.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results,&#8221; as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at&#160;www.sec.gov&#160;and&#160;www.pfizer.com. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Revenues of GSK&#8217;s Consumer Healthcare business included in this release were provided by GSK Consumer Healthcare management and converted from pounds sterling to U.S. dollars at an exchange rate of 1.30.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # # # # </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="s380B7AA47BBB70517AB5C62CF3B8A13A"></a></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pressreleaseexhimage1.jpg
<TEXT>
begin 644 pressreleaseexhimage1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "0 /H# 2(  A$! Q$!_\0
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M(_W:\%\P?WC7V[_P3/\  W]E_#75/'-Q"1)J^H[(G(ZQ0C _\?:3\JOC?'/
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MPOT&2+2H91_;/B.ZB(M;)"><M_$_7"#GUKZ8_P""<_\ P0F^,/[3=W8_$_\
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?DW)W>Y]5&,812BK(6BBBF6%%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
